Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study-Reference-Cited by-同舟云学术

Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study

Published:2007-01-19 Issue:2 Volume:191 Page:333-339
ISSN:0033-3158
Container-title:Psychopharmacology
language:en
Short-container-title:Psychopharmacology

Author:

Klein Nikolas,Sacher Julia,Geiss-Granadia Thomas,Mossaheb Nilufar,Attarbaschi Trawat,Lanzenberger Rupert,Spindelegger Christoph,Holik Alexander,Asenbaum Susanne,Dudczak Robert,Tauscher Johannes,Kasper Siegfried

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s00213-006-0666-y.pdf

Reference24 articles.

1. Backstrom I, Bergstrom M, Marcusson J (1989) High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue. Brain Res 486:261–268

2. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ, WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders (Allain H, Anderson I, Ayuso-Gutierrez JL, Baldwin D, Bech P, Benkert O, Berk M, Bitter I, Bourgeois ML, Burrows G, Cassano G, Cetkovich-Bakmas M, Cookson JC, da Costa D, Gheorghe MD, Heinze G, Higuchi T, Hirschfeld RM, Höschl C, Hoelsboer-Trachsler E, Kasper S, Katona C, Keller MB, Kulhara P, Kupfer DJ, Lecrubier Y, Leonard B, Licht RW, Lingjaerde O, Lublin H, Mendlewicz J, Mitchell P, Paykel ES, Puzynski S, Rush AJ, Rybakowski JK, Schweitzer I, Unützer J, Vestergaard P, Vieta E, Yamada K) (2002) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3:5–43

3. Baumann P, Larsen F (1995) The pharmacokinetics of citalopram. Rev Contemp Pharmacother 6:287–295

4. Colonna L, Andersen HF, Reines EH (2005) A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 21(10):1659–1668, (Oct)

5. Gutierrez MM, Rosenberg J, Abramowitz W (2003) An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther 25:1200–1210

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update Lessons from PET Imaging Part II: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antidepressants;Therapeutic Drug Monitoring;2024-01-24

2. A Review of Clinical Studies Assessing the Therapeutic Efficacy of Escitalopram: A Step Towards Development;CNS & Neurological Disorders - Drug Targets;2023-01

3. Systematic review and meta-analysis on the therapeutic reference range for escitalopram: Blood concentrations, clinical effects and serotonin transporter occupancy;Frontiers in Psychiatry;2022-10-17

4. One‐week escitalopram intake alters the excitation–inhibition balance in the healthy female brain;Human Brain Mapping;2022-01-22

5. Antidepressants: Molecular Aspects of SSRIs;NeuroPsychopharmacotherapy;2022